BioWorld

April 7, 2006

Tapestry Collects $25M For Lead Anticancer Compound

To move its lead cancer product into Phase II trials, Tapestry Pharmaceuticals Inc. closed a $25.5 million private placement with nine institutional investors. (BioWorld Today) Read More

Replidyne Files IPO For Up To $100M; Orapem Pending

Bioreactor To Bedside, Metastasis In Crosshairs

Aastrom Raising $25M For Adult Stem Cell Technology

Other News To Note

Clinic Roundup

U.S. Patent Disclosures

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 6, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...